Our results suggested that synergistic antiproliferative activity may be achieved by combining a dual mTORC1/2 inhibitor with Akt inhibitor treatment of established HCC cell lines, regardless of p53 status. The gene discussed is AKT1; the disease is hepatocellular carcinoma.